Arterial Thrombosis and the Role of Thrombophilia

ABSTRACT

Thrombophilia is a prominent risk factor for venous thromboembolism. The role of thrombophilia in determining the risk of arterial thrombotic events is less well defined. In this review, we summarize the existing literature on the relationship between thrombophilic defects and the risk of arterial thrombosis, in particular myocardial infarction and stroke. The six defects reviewed are the factor V Leiden mutation, the prothrombin G20210A mutation, protein C deficiency, protein S deficiency, antithrombin deficiency, and the antiphospholipid syndrome. We observed that substantial evidence supports an association between the presence of the antiphospholipid syndrome and the risk of myocardial infarction, particularly among people in whom the atherosclerotic burden is low. The literature contains no solid evidence to support an important relationship between the other thrombophilic defects reviewed and the risk of arterial thrombosis. We conclude that thrombophilia screening in unselected patient populations with myocardial infarction or ischemic stroke is not justified.

Thrombophilia - thrombosis - myocardial infarction - stroke

REFERENCES

• 1 Middeldorp S, Prins M H, Buller H R. No indication for thrombophilia screening in patients with idiopathic venous thromboembolism and their relatives.  Ned Tijdschr Geneeskd. 2001;  145 1047-1051
• 2 Cohn D M, Middeldorp S. A multicentre randomised clinical trial to evaluate the benefit of testing for thrombophilia following a first venous thromboembolism: the NOSTRADAMUS study.  Ned Tijdschr Geneeskd. 2007;  151 371-373
• 3 Bertina R M, Koeleman B P, Koster T et al.. Mutation in blood coagulation factor V associated with resistance to activated protein C.  Nature. 1994;  369 64-67
• 4 Vandenbroucke J P, Koster T, Briet E et al.. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation.  Lancet. 1994;  344 1453-1457
• 5 Bertina R M, Reitsma P H, Rosendaal F R, Vandenbroucke J P. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis.  Thromb Haemost. 1995;  74 449-453
• 6 Ridker P M, Hennekens C H, Lindpaintner K et al.. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men.  N Engl J Med. 1995;  332 912-917
• 7 Cushman M, Rosendaal F R, Psaty B M et al.. Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: results from the Cardiovascular Health Study.  Thromb Haemost. 1998;  79 912-915
• 8 Juul K, Tybjaerg-Hansen A, Steffensen R et al.. Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses.  Blood. 2002;  100 3-10
• 9 Boekholdt S M, Bijsterveld N R, Moons A H et al.. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review.  Circulation. 2001;  104 3063-3068
• 10 Mansourati J, Da Costa A, Munier S et al.. Prevalence of factor V Leiden in patients with myocardial infarction and normal coronary angiography.  Thromb Haemost. 2000;  83 822-825
• 11 Rosendaal F R, Siscovick D S, Schwartz S M et al.. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women.  Blood. 1997;  89 2817-2821
• 12 Atherosclerosis Thrombosis and Vascular Biology Italian Study Group . No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age.  Circulation. 2003;  107 1117-1122
• 13 Hankey G J, Eikelboom J W, van Bockxmeer F M et al.. Inherited thrombophilia in ischemic stroke and its pathogenic subtypes.  Stroke. 2001;  32 1793-1799
• 14 Longstreth Jr W T, Rosendaal F R, Siscovick D S et al.. Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A).  Stroke. 1998;  29 577-580
• 15 Lalouschek W, Schillinger M, Hsieh K et al.. Matched case-control study on factor V Leiden and the prothrombin G20210A mutation in patients with ischemic stroke/transient ischemic attack up to the age of 60 years.  Stroke. 2005;  36 1405-1409
• 16 Zenz W, Bodo Z, Plotho J et al.. Factor V Leiden and prothrombin gene G 20210 A variant in children with ischemic stroke.  Thromb Haemost. 1998;  80 763-766
• 17 Kenet G, Sadetzki S, Murad H et al.. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children.  Stroke. 2000;  31 1283-1288
• 18 Poort S R, Rosendaal F R, Reitsma P H, Bertina R M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.  Blood. 1996;  88 3698-3703
• 19 Gehring N H, Frede U, Neu-Yilik G et al.. Increased efficiency of mRNA 3′ end formation: a new genetic mechanism contributing to hereditary thrombophilia.  Nat Genet. 2001;  28 389-392
• 20 Soria J M, Almasy L, Souto J C et al.. Linkage analysis demonstrates that the prothrombin G20210A mutation jointly influences plasma prothrombin levels and risk of thrombosis.  Blood. 2000;  95 2780-2785
• 21 Margaglione M, Brancaccio V, Giuliani N et al.. Increased risk for venous thrombosis in carriers of the prothrombin G→A20210 gene variant.  Ann Intern Med. 1998;  129 89-93
• 22 Doggen C J, Cats V M, Bertina R M, Rosendaal F R. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A.  Circulation. 1998;  97 1037-1041
• 23 Bank I, Libourel E J, Middeldorp S et al.. Prothrombin 20210A mutation: a mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study.  Arch Intern Med. 2004;  164 1932-1937
• 24 Ridker P M, Hennekens C H, Miletich J P. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men.  Circulation. 1999;  99 999-1004
• 25 Croft S A, Daly M E, Steeds R P et al.. The prothrombin 20210A allele and its association with myocardial infarction.  Thromb Haemost. 1999;  81 861-864
• 26 Smiles A M, Jenny N S, Tang Z et al.. No association of plasma prothrombin concentration or the G20210A mutation with incident cardiovascular disease: results from the Cardiovascular Health Study.  Thromb Haemost. 2002;  87 614-621
• 27 De Stefano V, Chiusolo P, Paciaroni K et al.. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients.  Blood. 1998;  91 3562-3565
• 28 Austin H, Chimowitz M I, Hill H A et al.. Cryptogenic stroke in relation to genetic variation in clotting factors and other genetic polymorphisms among young men and women.  Stroke. 2002;  33 2762-2768
• 29 Pezzini A, Grassi M, Del Zotto E et al.. Cumulative effect of predisposing genotypes and their interaction with modifiable factors on the risk of ischemic stroke in young adults.  Stroke. 2005;  36 533-539
• 30 Koster T, Rosendaal F R, Briet E et al.. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study).  Blood. 1995;  85 2756-2761
• 31 Martinelli I, Mannucci P M, De Stefano V et al.. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families.  Blood. 1998;  92 2353-2358
• 32 Peterman M A, Roberts W C. Syndrome of protein C deficiency and anterior wall acute myocardial infarction at a young age from a single coronary occlusion with otherwise normal coronary arteries.  Am J Cardiol. 2003;  92 768-770
• 33 Tiong I Y, Alkotob M L, Ghaffari S. Protein C deficiency manifesting as an acute myocardial infarction and ischaemic stroke.  Heart. 2003;  89 E7-E8
• 34 Hayashi K, Sone T, Kondoh J et al.. Prevalence of activated protein C resistance in acute myocardial infarction in Japan.  Jpn Heart J. 1997;  38 769-778
• 35 Segev A, Ellis M H, Segev F et al.. High prevalence of thrombophilia among young patients with myocardial infarction and few conventional risk factors.  Int J Cardiol. 2005;  98 421-424
• 36 Rallidis L S, Belesi C I, Maniouudaki H S et al.. Myocardial infarction under the age of 36: prevalence of thrombophilic disorders.  Thromb Haemost. 2003;  90 272-278
• 37 Zorio E, Navarro S, Medina P et al.. Circulating activated protein C is reduced in young survivors of myocardial infarction and inversely correlates with the severity of coronary lesions.  J Thromb Haemost. 2006;  4 1530-1536
• 38 Koller H, Stoll G, Sitzer M et al.. Deficiency of both protein C and protein S in a family with ischemic strokes in young adults.  Neurology. 1994;  44 1238-1240
• 39 Grewal R P, Goldberg M A. Stroke in protein C deficiency.  Am J Med. 1990;  89 538-539
• 40 Kohler J, Kasper J, Witt I, von Reutern G M. Ischemic stroke due to protein C deficiency.  Stroke. 1990;  21 1077-1080
• 41 Camerlingo M, Finazzi G, Casto L et al.. Inherited protein C deficiency and nonhemorrhagic arterial stroke in young adults.  Neurology. 1991;  41 1371-1373
• 42 De Stefano V, Leone G, Micalizzi P et al.. Arterial thrombosis as clinical manifestation of congenital protein C deficiency.  Ann Hematol. 1991;  62 180-183
• 43 Martinez H R, Rangel-Guerra R A, Marfil L J. Ischemic stroke due to deficiency of coagulation inhibitors. Report of 10 young adults.  Stroke. 1993;  24 19-25
• 44 Douay X, Lucas C, Caron C, Goudemand J, Leys D. Antithrombin, protein C and protein S levels in 127 consecutive young adults with ischemic stroke.  Acta Neurol Scand. 1998;  98 124-127
• 45 Munts A G, van Genderen P J, Dippel D W, van Kooten F, Koudstaal P J. Coagulation disorders in young adults with acute cerebral ischaemia.  J Neurol. 1998;  245 21-25
• 46 Ganesan V, McShane M A, Liesner R et al.. Inherited prothrombotic states and ischaemic stroke in childhood.  J Neurol Neurosurg Psychiatry. 1998;  65 508-511
• 47 deVeber G, Monagle P, Chan A et al.. Prothrombotic disorders in infants and children with cerebral thromboembolism.  Arch Neurol. 1998;  55 1539-1543
• 48 Gandrille S, Borgel D, Ireland H et al.. Protein S deficiency: a database of mutations. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.  Thromb Haemost. 1997;  77 1201-1214
• 49 Comp P C, Nixon R R, Cooper M R, Esmon C T. Familial protein S deficiency is associated with recurrent thrombosis.  J Clin Invest. 1984;  74 2082-2088
• 50 Comp P C, Esmon C T. Recurrent venous thromboembolism in patients with a partial deficiency of protein S.  N Engl J Med. 1984;  311 1525-1528
• 51 Simmonds R E, Ireland H, Lane D A et al.. Clarification of the risk for venous thrombosis associated with hereditary protein S deficiency by investigation of a large kindred with a characterized gene defect.  Ann Intern Med. 1998;  128 8-14
• 52 Makris M, Leach M, Beauchamp N J et al.. Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited deficiencies of protein S.  Blood. 2000;  95 1935-1941
• 53 Cakir O, Ayyildiz O, Oruc A, Eren N. A young adult with coronary artery and jugular vein thrombosis: a case report of combined protein S and protein C deficiency.  Heart Vessels. 2002;  17 74-76
• 54 Manzar K J, Padder F A, Conrad A R, Freeman I, Jonas E A. Acute myocardial infarction with normal coronary artery: a case report and review of literature.  Am J Med Sci. 1997;  314 342-345
• 55 Beattie S, Norton M, Doll D. Coronary thrombosis associated with inherited protein S deficiency: a case report.  Heart Lung. 1997;  26 76-79
• 56 Rudnicka A R, Miller G J, Nelson T, Doray D, Comp P C. An association between plasma free protein s concentration and risk of coronary heart disease in middle-aged men.  Thromb Res. 2001;  101 1-11
• 57 Girolami A, Simioni P, Lazzaro A R, Cordiano I. Severe arterial cerebral thrombosis in a patient with protein S deficiency (moderately reduced total and markedly reduced free protein S): a family study.  Thromb Haemost. 1989;  61 144-147
• 58 Green D, Otoya J, Oriba H, Rovner R. Protein S deficiency in middle-aged women with stroke.  Neurology. 1992;  42 1029-1033
• 59 Carod-Artal F J, Nunes S V, Portugal D, Silva T V, Vargas A P. Ischemic stroke subtypes and thrombophilia in young and elderly Brazilian stroke patients admitted to a rehabilitation hospital.  Stroke. 2005;  36 2012-2014
• 60 Barinagarrementeria F, Cantu-Brito C, De La Pena A, Izaguirre R. Prothrombotic states in young people with idiopathic stroke. A prospective study.  Stroke. 1994;  25 287-290
• 61 Gunther G, Junker R, Strater R et al.. Symptomatic ischemic stroke in full-term neonates: role of acquired and genetic prothrombotic risk factors.  Stroke. 2000;  31 2437-2441
• 62 Mateo J, Oliver A, Borrell M, Sala N, Fontcuberta J. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism-results of the Spanish Multicentric Study on Thrombophilia (EMET-Study).  Thromb Haemost. 1997;  77 444-451
• 63 van Boven H H, Vandenbroucke J P, Briet E, Rosendaal F R. Gene-gene and gene-environment interactions determine risk of thrombosis in families with inherited antithrombin deficiency.  Blood. 1999;  94 2590-2594
• 64 Peeters S, Vandenplas Y, Jochmans K et al.. Myocardial infarction in a neonate with hereditary antithrombin III deficiency.  Acta Paediatr. 1993;  82 610-613
• 65 Dacosta A, Tardy-Poncet B, Isaaz K et al.. Prevalence of factor V Leiden (APCR) and other inherited thrombophilias in young patients with myocardial infarction and normal coronary arteries.  Heart. 1998;  80 338-340
• 66 Arima T, Motomura M, Nishiura Y et al.. Cerebral infarction in a heterozygote with variant antithrombin III.  Stroke. 1992;  23 1822-1825
• 67 Strater R, Vielhaber H, Kassenbohmer R et al.. Genetic risk factors of thrombophilia in ischaemic childhood stroke of cardiac origin. A prospective ESPED survey.  Eur J Pediatr.. 1999;  158(suppl 3) S122-S125
• 68 Miyakis S, Lockshin M D, Atsumi T et al.. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).  J Thromb Haemost. 2006;  4 295-306
• 69 Pierangeli S S, Chen P P, Gonzalez E B. Antiphospholipid antibodies and the antiphospholipid syndrome: an update on treatment and pathogenic mechanisms.  Curr Opin Hematol. 2006;  13 366-375
• 70 de Laat B, Wu X X, van Lummel M et al.. Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5.  Blood. 2007;  109 1490-1494
• 71 Turiel M, Sarzi-Puttini P, Peretti R et al.. Thrombotic risk factors in primary antiphospholipid syndrome: a 5-year prospective study.  Stroke. 2005;  36 1490-1494
• 72 Meroni P L, di Simoni N, Testoni C et al.. Antiphospholipid antibodies as cause of pregnancy loss.  Lupus. 2004;  13 649-652
• 73 Cervera R, Piette J C, Font J et al.. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.  Arthritis Rheum. 2002;  46 1019-1027
• 74 Asherson R A. The catastrophic antiphospholipid (Asherson's) syndrome.  Autoimmun Rev. 2006;  6 64-67
• 75 Brey R L, Abbott R D, Curb J D et al.. Beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu heart program.  Stroke. 2001;  32 1701-1706
• 76 Zuckerman E, Toubi E, Shiran A et al.. Anticardiolipin antibodies and acute myocardial infarction in non-systemic lupus erythematosus patients: a controlled prospective study.  Am J Med. 1996;  101 381-386
• 77 Zavaleta N E, Montes R M, Soto M E, Vanzzini N A, Amigo M C. Primary antiphospholipid syndrome: a 5-year transesophageal echocardiographic followup study.  J Rheumatol. 2004;  31 2402-2407
• 78 Brey R L, Hart R G, Sherman D G, Tegeler C H. Antiphospholipid antibodies and cerebral ischemia in young people.  Neurology. 1990;  40 1190-1196
• 79 Nencini P, Baruffi M C, Abbate R et al.. Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia.  Stroke. 1992;  23 189-193
• 80 Toschi V, Motta A, Castelli C et al.. High prevalence of antiphosphatidylinositol antibodies in young patients with cerebral ischemia of undetermined cause.  Stroke. 1998;  29 1759-1764
• 81 Brey R L, Stallworth C L, McGlasson D L et al.. Antiphospholipid antibodies and stroke in young women.  Stroke. 2002;  33 2396-2400
• 82 Hojnik M, George J, Ziporen L, Shoenfeld Y. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome.  Circulation. 1996;  93 1579-1587
• 83 Krause I, Lev S, Fraser A et al.. Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome.  Ann Rheum Dis. 2005;  64 1490-1493
• 84 Nityanand S, Bergmark C, de Faire U et al.. Antibodies against endothelial cells and cardiolipin in young patients with peripheral atherosclerotic disease.  J Intern Med. 1995;  238 437-443
• 85 Puisieux F, de Groote P, Masy E et al.. Association between anticardiolipin antibodies and mortality in patients with peripheral arterial disease.  Am J Med. 2000;  109 635-641